AVJ-514 Trial　― Baseline Characteristics and 30-Day Outcomes Following MitraClip&lt;sup&gt;®&lt;/sup&gt; Treatment in a Japanese Cohort ―

Hayashida, Kentaro; Yasuda, Satoshi; Matsumoto, Takashi; Amaki, Makoto; Mizuno, Shingo; Tobaru, Tetsuya; Jujo, Kentaro; Ootomo, Tatsushi; Yamaguchi, Junichi; Fukuda, Keiichi; Saïto, Shigeru; Foster, Elyse; Qasim, Atif; Kitakaze, Masafumi; Yozu, Ryohei; Takayama, Morimasa

doi:10.1253/circj.cj-17-0115

Cited by 36 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, overall 1-year survival rate was comparable in older age group compared to younger aged group. As data involving transcatheter mitral valve repair in the Asian population are scarce,5) the fact that MitraClip showed favorable results in the Asian population and that such results are consistent with previous studies involving western population could be meaningful.…”

supporting

confidence: 82%

Transcatheter Mitral Valve Repair: Growing Evidence Regarding It's Efficacy and Optimal Indication

Choi

Hong

2019

Korean Circ J

View full text Add to dashboard Cite

supporting

confidence: 82%

Transcatheter Mitral Valve Repair: Growing Evidence Regarding It's Efficacy and Optimal Indication

Choi

Hong

2019

Korean Circ J

View full text Add to dashboard Cite

“…Among DMR patients, the acute procedural success rate was 87.5% and 81.3% had MR grade ≤2+ at 30 days. [ 16 ] The proportion of patients with NYHA functional class III/IV was reduced from 37.5% to 6.3%. No deaths were reported.…”

Section: Mitraclip Use In Degenerative Mitral Regurgitationmentioning

confidence: 99%

Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation

et al. 2021

Self Cite

View full text Add to dashboard Cite

Transcatheter mitral valve repair with the MitraClip, a catheter-based percutaneous edge-to-edge repair technique to correct mitral regurgitation (MR), has been demonstrated in Western studies to be an effective and safe MR treatment strategy. However, randomised clinical trial data on its use in Asian-Pacific patients is limited. Hence, the Asian Pacific Society of Cardiology convened an expert panel to review the available literature on MitraClip and to develop consensus recommendations to guide clinicians in the region. The panel developed statements on the use of MitraClip for the management of degenerative MR, functional MR, and other less common indications, such as acute MR, dynamic MR, hypertrophic obstructive cardiomyopathy, and MR after failed surgical repair. Each statement was voted on by each panel member and consensus was reached when 80% of experts voted ‘agree’ or ‘neutral’. This consensus-building process resulted in 10 consensus recommendations to guide general cardiologists in the evaluation and management of patients in whom MitraClip treatment is being contemplated.

show abstract

“…In Japan, the AVJ-514 trial was a prospective multi-centre observational trial, demonstrating the use of MitraClip for the purpose of regulatory approval. 30) 30 patients were enrolled with the mean age of 80.4±7.0 years, STS score of 10.3±6.59%. The 53.3% of the patients had DMR while the rest were FMR.…”

Section: Approved Use and Experience In Asiamentioning

confidence: 99%

Percutaneous Edge-to-Edge Mitral Valve Repair

Yeo

Wong

2020

Korean Circ J

View full text Add to dashboard Cite

Percutaneous edge-to-edge mitral valve repair, using the MitraClip device for severe mitral regurgitation (MR) was first introduced in 2003. Since then, more than 100,000 cases have been performed worldwide and it remains the most established percutaneous therapy available for the treatment of severe MR. Currently, it is indicated for severe, symptomatic functional MR in patients who continue to have significant symptoms despite optimal guideline directed medical therapy, as well as in symptomatic patients with severe degenerative MR who are deemed too high risk for conventional surgical therapy in the opinion of the heart team. In this paper, we discuss the evolution of the MitraClip device, the clinical studies supporting its use as well as the important concept of proportionate and disproportionate MR.

show abstract

AVJ-514 Trial　― Baseline Characteristics and 30-Day Outcomes Following MitraClip<sup>®</sup> Treatment in a Japanese Cohort ―

Cited by 36 publications

References 26 publications

Transcatheter Mitral Valve Repair: Growing Evidence Regarding It's Efficacy and Optimal Indication

Transcatheter Mitral Valve Repair: Growing Evidence Regarding It's Efficacy and Optimal Indication

Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation

Percutaneous Edge-to-Edge Mitral Valve Repair

Contact Info

Product

Resources

About

AVJ-514 Trial ― Baseline Characteristics and 30-Day Outcomes Following MitraClip<sup>®</sup> Treatment in a Japanese Cohort ―

Cited by 36 publications

References 26 publications

Transcatheter Mitral Valve Repair: Growing Evidence Regarding It's Efficacy and Optimal Indication

Transcatheter Mitral Valve Repair: Growing Evidence Regarding It's Efficacy and Optimal Indication

Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation

Percutaneous Edge-to-Edge Mitral Valve Repair

Contact Info

Product

Resources

About

AVJ-514 Trial　― Baseline Characteristics and 30-Day Outcomes Following MitraClip<sup>®</sup> Treatment in a Japanese Cohort ―